Company news
LIR Life Sciences Corp. news in 2026
LIR Life Sciences Corp.'s news releases, calls and decks from 2026, newest first.
LIR Life Sciences Signs Development Services Agreement with Oxygen Handel GmbH (OH) to Advance Regulatory and Preclinical Roadmap for Transdermal Obesity Pipeline
July 16, 2026
LIR Life Sciences Completes Comparative Animal Study Showing Successful Protamine-Enhanced Permeation Transport of Both Semaglutide and Tirzepatide
June 17, 2026
LIR Life Sciences Announces Initiation of Phase 1 Macromolecule-Enabled Transdermal Delivery Development with Neuland Laboratories
May 22, 2026
LIR Life Sciences Launches Ex Vivo Animal Study to Evaluate Protamine Enhanced Transdermal Transport of Larger Format Therapeutic Molecules
April 28, 2026
LIR Life Sciences Corp. Announces Agreement with Resilience BioSciences Inc.
April 20, 2026
LIR Life Sciences Reports Positive Interim Preclinical Results from Comparative Animal Study of Novel CPP-Enabled Transdermal Delivery of GLP/GIP-Based Therapies
January 29, 2026
LIR Life Sciences Completes Design of Ex Vivo Animal Study to Evaluate Novel Transdermal Agents for Transport of Larger Therapeutic Molecules
January 22, 2026
LIR Life Sciences Launches Comparative Animal Study to Advance Transdermal Delivery of Second Generation GLP/GIP-based Obesity Therapies
January 15, 2026
LIR Life Engages Neuland Labs to Advance Development of Cell Penetrating Peptides for Transdermal GLP-1/GIP Platform
January 8, 2026